Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients

This study is collecting real-world data on men with metastatic prostate cancer — cancer that has spread beyond the prostate — to better understand how different treatment combinations (chemotherapy, hormone-blocking drugs, or radiation) affect outcomes in everyday clinical practice. **You may be eligible if...** - You have been diagnosed with prostate cancer that has spread (metastatic disease) - You received treatment with docetaxel (a chemotherapy), hormone-blocking drugs (called ARPIs), or radiation between January 2015 and December 2027 - Your medical records are available for data collection - You had not previously received treatment for the metastatic stage (aside from hormonal therapy started up to 6 months before docetaxel) **You may NOT be eligible if...** - Your cancer type is not adenocarcinoma (the most common type) - You received multiple lines of hormone-blocking therapy before this stage - You already received chemotherapy or hormone-blocking drugs for treatment-resistant (castration-resistant) prostate cancer Talk to your doctor to see if this trial is right for you.